Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome <scp>P450</scp> in patients with obesity-Reference-Cited by-同舟云学术

Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity

Published:2022-09-08 Issue:11 Volume:15 Page:2685-2696
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Kvitne Kine Eide¹^ORCID,Åsberg Anders¹²^ORCID,Johnson Line K.³,Wegler Christine⁴⁵,Hertel Jens K.³,Artursson Per⁶^ORCID,Karlsson Cecilia⁷⁸^ORCID,Andersson Shalini⁹,Sandbu Rune³¹⁰,Skovlund Eva¹¹,Christensen Hege¹,Jansson‐Löfmark Rasmus⁵,Hjelmesæth Jøran³¹²,Robertsen Ida¹

Affiliation:

1. Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy University of Oslo Oslo Norway

2. Department of Transplantation Medicine Oslo University Hospital Oslo Norway

3. The Morbid Obesity Center Vestfold Hospital Trust Tønsberg Norway

4. Department of Pharmacy Uppsala University Uppsala Sweden

5. DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM) BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden

6. Department of Pharmacy and Science for Life Laboratory Uppsala University Uppsala Sweden

7. Late‐stage Development, Cardiovascular, Renal and Metabolism (CVRM) BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden

8. Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy University of Gothenburg Gothenburg Sweden

9. Oligonucleotide Discovery Discovery Sciences, R&D, AstraZeneca Gothenburg Sweden

10. Department of Surgery Vestfold Hospital Trust Tønsberg Norway

11. Department of Public Health and Nursing Norwegian University of Science and Technology, NTNU Trondheim Norway

12. Department of Endocrinology, Morbid Obesity and Preventive Medicine, Institute of Clinical Medicine University of Oslo Oslo Norway

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13394

Reference44 articles.

1. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

2. Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals

3. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

4. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”

5. Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactions;British Journal of Clinical Pharmacology;2024-01-25

2. What is the impact of type 2 diabetes mellitus on CYP450 metabolic activities?;Expert Opinion on Drug Metabolism & Toxicology;2023-11-25

3. The alteration of drug metabolism enzymes and pharmacokinetic parameters in nonalcoholic fatty liver disease: current animal models and clinical practice;Drug Metabolism Reviews;2023-04-28

4. Initiation of glucose‐lowering drugs reduces the anticoagulant effect of warfarin—But not through altered drug metabolism in patients with type 2 diabetes;British Journal of Clinical Pharmacology;2023-04-14

5. Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease;Nature Communications;2023-03-17